Doctor survey supports growth of Neurocrine’s Ingrezza, says JPMorgan

JPMorgan analyst Anupam Rama says his survey of 20 psychiatrists and five neurologists continues to support the launch and growth trajectory of Neurocrine Biosciences’ Ingrezza. It is clear that both Ingrezza and Teva’s (TEVA) Austedo have a place in the treatment paradigm, Rama tells investors in a research note. However, on average, the clinical profile of Ingrezza is preferred by physicians and this resulted in higher market share estimates by those surveyed, the analyst adds. He notes this is the second U.S. physician survey he has conducted in less than 12 months and that both have shown favorable trends/data points for Ingrezza. Rama, however, reiterates a Neutral rating on Neurocrine as he prefers to wait for a better entry point before adding to positions.
https://thefly.com/landingPageNews.php?id=2884139